SARS-CoV-2 RT-PCR Assay Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing SARS-CoV-2 are not sufficiently sensitive and specific, particularly in detecting low viral loads and asymptomatic cases, due to limitations in viral culture, biosafety requirements, and cross-reactivity with SARS-CoV, necessitating the development of more effective diagnostic tools.
Innovation Solution
The use of specific nucleic acid sequences and probes targeting SARS-CoV-2 genes, such as RdRp/Helicase, Spike, and Nucleocapsid, for real-time RT-PCR assays that provide enhanced sensitivity and specificity, allowing for detection in various clinical samples with reduced cross-reactivity with other coronaviruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral culture is used for establishing acute diagnosis, then virus isolation can be achieved, but it takes at least three days for clear cytopathic effects and requires biosafety level-3 facilities which are not available in most healthcare institutions
Solution Approach 1:
The patent replaces the mechanical/biological system of viral culture with a molecular biology system (RT-PCR). Instead of relying on viral replication in cell cultures to produce cytopathic effects, the invention uses reverse transcription polymerase chain reaction to directly detect and amplify viral RNA genetic material, achieving rapid diagnosis without requiring biosafety level-3 facilities or waiting for cytopathic effects to develop
Solution Approach 2:
The patent uses PCR amplification to create copies of the viral RNA genome. By targeting specific conserved regions of the SARS-CoV-2 genome and amplifying them exponentially, the method generates sufficient detectable signal from minimal initial viral RNA, enabling sensitive detection without needing to culture the virus in cells
2Ease of operation
If serum antibody and antigen detection tests are used, then diagnosis can be performed, but there may be cross-reactivity with SARS-CoV which shares high degree of nucleotide identity
Solution Approach 1:
The patent applies local quality by designing primers and probes that target specific, unique regions of the SARS-CoV-2 genome rather than using general coronavirus targets. By selecting highly specific genomic regions and designing sequences with maximum discrimination between SARS-CoV-2 and SARS-CoV, the method achieves high specificity while maintaining operational simplicity
Solution Approach 2:
The patent changes the detection parameter from antibody/antigen detection to direct viral RNA detection through RT-PCR. This parameter change allows for earlier detection (before antibody development) and enables use of highly specific molecular targets that can distinguish SARS-CoV-2 from SARS-CoV through sequence-specific primer and probe design
3Measurement precision
If real-time RT-PCR assays are developed with high sensitivity, then low viral loads can be detected, but assay complexity and requirements for validation increase
Solution Approach 1:
The patent segments the diagnostic challenge into three separate, validated RT-PCR assays targeting different genomic regions (RdRp, E, and N genes). This segmentation allows each assay to be optimized for high sensitivity independently, and the use of multiple targets increases overall detection capability while maintaining manageable complexity through modular design and validation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution significantly improves the detection of SARS-CoV-2 RNA, particularly in cases with low viral loads, and demonstrates specificity, reducing false negatives and cross-reactivity, thereby aiding in identifying asymptomatic cases and managing the COVID-19 epidemic effectively.
Implementation Method 1
real-time RT-PCR assays
Implementation Method 2
real-time RT-PCR assays
Implementation Method 3
probes modified for use a real-time polymerase chain reaction, and include, for example, one or more fluorescent reporters
Data Source
AI summary
Provided a nucleic acid probe or primer for the detection of SARS-CoV-2 RdRp/Helicase, Spike (S) or Nucleocapsid (N), and its use in a method of detecting SARS-CoV-2 in a sample. The nucleic acid probe or primer is consisting of a nucleic acid sequence of any of SEQ ID NOs: 1-12.